---
type: "Topics"
locale: "en"
url: "https://longbridge.com/en/topics/41673436.md"
description: "$WUXI BIO(02269.HK) has barely moved. $LONGBIO-B(01779.HK) started to dip slightly less than a week after listing. $Recursion Pharmaceuticals(RXRX.US) fell three percentage points. The recent script for innovative drug stocks has been "BD-driven big orders create a pulse," while on days without concrete deals, they all lie flat collectively. For a newly listed allergy-sector stock like $LONGBIO-B(01779.HK), why did its first-day hype fade so quickly? Is it the routine withdrawal of IPO subscription funds, or is the market becoming picky again about biotechs without commercialized products? It's more likely the former—the scarcity of the IgE target remains, but we need to wait for the data to speak."
datetime: "2026-06-10T10:44:02.000Z"
locales:
  - [en](https://longbridge.com/en/topics/41673436.md)
  - [zh-CN](https://longbridge.com/zh-CN/topics/41673436.md)
  - [zh-HK](https://longbridge.com/zh-HK/topics/41673436.md)
author: "[软乎乎的小熊](https://longbridge.com/en/profiles/27330473.md)"
generator: "portal-rs"
---

# $WUXI BIO(02269.HK) has barely moved. $LONGBIO-B(0…


### Related Stocks

- [02269.HK](https://longbridge.com/en/quote/02269.HK.md)
- [01779.HK](https://longbridge.com/en/quote/01779.HK.md)
- [RXRX.US](https://longbridge.com/en/quote/RXRX.US.md)
- [WXXWY.US](https://longbridge.com/en/quote/WXXWY.US.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**